The second petition calling for the insurance reimbursement of the breast cancer drug 'Troldelvy (sacituzumab govitecan-hziy)' has again garnered over 50,000 signatures.

This is the second petition filed after the first in January that garnered 50,000 signatures. Patients are growing increasingly desperate, as 3 months have passed with little news heard on Troldelvy’s reimbursement progress. Unfortunately, with the 22nd National Assembly currently in session, it is unlikely that the agenda will be reviewed by the relevant committee.

The petitioner, who described herself as a Stage IV triple-negative breast cancer (TNBC) patient on the petition board, wrote, "My tumor is growing too fast